Johanna Mäenpää

Professor

University of Tampere
Country flagFinland

Research Interests

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Explore related searches

About

Johanna Mäenpää is a Professor at the University of Tampere in Finland. Her research primarily focuses on oncology, with recent contributions including studies on treatments for ovarian cancer. Notably, she was involved in the randomized phase III trial examining Atezolizumab, Bevacizumab, and chemotherapy for newly diagnosed stage III or IV ovarian cancer.

Articles (8)

Year:

2026

The management of advanced epithelial ovarian cancer (AOC) has undergone significant advancements with the emergence of molecular diagnostics, particularly in predicting responses to PARP inhibitors (PARPi) based on homologous recombination deficiency (HRD) status. However, understanding sensitivity and resistance beyond HRD status remains elusive. This study aims to explore molecular factors that may elucidate why HRD status does not consistently predict PARPi sensitivity. Therefore, we conducted a post hoc translational analysis of formalin-fixed paraffin-embedded tumor samples from the ENGOT-ov24/NSGO-AVANOVA part 1 and 2 trial (NCT02354131), focusing on alterations pertaining radiologic response and progression-free survival (PFS). DNA sequencing was performed using the TruSight Oncology 500 HT gene panel, with variants classified according to recent guidelines. HRD status had been assessed by Myriad MyChoice CDx. We identified, among 92 patients in the ENGOT-ov24/NSGO-AVANOVA part 1 and 2 trial, 151 pathogenic or likely pathogenic variants across 81 samples. PARPi-sensitizing variants were found in two out of 10 HRD-negative samples from patients with clinical benefit (PFS ≥12 months), whereas three out of 10 HRD-positive samples from patients having no benefit (PFS ≤6 months) harbored variants associated with PARPi resistance. Additionally, analysis of BRCA1 variants revealed that truncating variants in exon 11 correlated with clinical benefit when niraparib was combined with bevacizumab. Conclusively, our findings highlight the complexity of PARPi response in AOC and underscore the importance of exploring somatic variants beyond HRD status. Further investigation into exon 11 variants of BRCA1 and the potential of combination treatment is warranted. Significance: The irregular response to PARPi in HRD-positive and -negative tumors highlights the need for identifying additional biomarkers. This study explores the mutational landscape beyond HRD status in AOC, ultimately advancing precision oncology in future clinical practice.

Year:

2025

BRCA1 (top) and BRCA2 (bottom) with variants found in AVANOVA1&2 colored by treatment response (see legend). BRCA1 : Transcript NM_007294.4. In total, 1,863 aa. RING domain (aa 2–101), PALB2 -binding domain (also called coiled-coil domain; aa 1,391–1,424), BRCT repeats (aa 1,650–1857), and exon 11 (aa 224–1,366). BRCA2 : Transcript NM_000059.4. In total, 3,418 aa. PALB2 -binding domain (aa 10–40), DNA-binding domain (aa 2,481–3,186), and exons 10 and 11 (aa 266–2,281).

Year:

2024

Oncoplot showing pathogenic gene alterations. The plot is split into groups by cellular pathways affected by the alteration on the vertical axis and clinical outcome (clinical benefit: PFS ≥12 months, no benefit: PFS ≤6 months) on the horizontal axis. Each column represents one patient. In total, 81 patient samples. See color guide reflecting specific alterations below the plot. # = Reason of “end of treatment” other than progressive disease. Integer “HRD-status and GIS” = the exact GIS reported by MyChoice.

Year:

2024

PFS in months colored by HRD status. Dashed lines at 6 and 12 months illustrate cutoff for “no benefit” and “clinical benefit”. X -axis indicates the number of patients. Reason for end of treatment other than progression: # = toxicity, $ = partial withdrawal of consent (study assessments continued), ¤ = investigator decision, and “…” = no progression at study closure. See guide in plot for color explanations.

Year:

2024

The management of advanced epithelial ovarian cancer (AOC) has undergone significant advancements with the emergence of molecular diagnostics, particularly in predicting responses to PARP inhibitors (PARPi) based on homologous recombination deficiency (HRD) status. However, understanding sensitivity and resistance beyond HRD status remains elusive. This study aims to explore molecular factors that may elucidate why HRD status does not consistently predict PARPi sensitivity. Therefore, we conducted a post hoc translational analysis of formalin-fixed paraffin-embedded tumor samples from the ENGOT-ov24/NSGO-AVANOVA part 1 and 2 trial (NCT02354131), focusing on alterations pertaining radiologic response and progression-free survival (PFS). DNA sequencing was performed using the TruSight Oncology 500 HT gene panel, with variants classified according to recent guidelines. HRD status had been assessed by Myriad MyChoice CDx. We identified, among 92 patients in the ENGOT-ov24/NSGO-AVANOVA part 1 and 2 trial, 151 pathogenic or likely pathogenic variants across 81 samples. PARPi-sensitizing variants were found in two out of 10 HRD-negative samples from patients with clinical benefit (PFS ≥12 months), whereas three out of 10 HRD-positive samples from patients having no benefit (PFS ≤6 months) harbored variants associated with PARPi resistance. Additionally, analysis of BRCA1 variants revealed that truncating variants in exon 11 correlated with clinical benefit when niraparib was combined with bevacizumab. Conclusively, our findings highlight the complexity of PARPi response in AOC and underscore the importance of exploring somatic variants beyond HRD status. Further investigation into exon 11 variants of BRCA1 and the potential of combination treatment is warranted. Significance: The irregular response to PARPi in HRD-positive and -negative tumors highlights the need for identifying additional biomarkers. This study explores the mutational landscape beyond HRD status in AOC, ultimately advancing precision oncology in future clinical practice.

Year:

2024

Background Clinical trials of immune checkpoint inhibitors in epithelial ovarian cancer (EOC) have not shown clear survival benefit, likely due to the complex immunosuppressive mechanisms of the EOC tumor microenvironment. Still, certain patients experience long-term treatment benefit. However, we lack reliable biomarkers for distinguishing dominant immunosuppressive mechanisms and for identifying patients with EOC who are responsive to immunotherapy. The present high-dimensional single-cell study analyzed patients with relapsed EOC enrolled in arm A of the NSGO-OV-UMB1/ENGOT-OV30 trial, wherein the patients underwent combination oleclumab (anti-CD73) and durvalumab (anti-PD-L1) immunotherapy. The objective of the study was the identification of blood-based immunophenotypic signatures conducive to the development of improved strategies for patient selection, response monitoring, and personalized targeting of immunosuppressive mechanisms. Methods A 40-marker suspension mass cytometry panel was utilized for comprehensive phenotypic and functional characterization of longitudinally sampled peripheral blood leukocytes from patients. Artificial neural network-based unsupervised clustering and manual metacluster curation were used to identify leukocyte subsets for differential discovery and correlation analyses. Results At baseline, short-term and long-term survivors differed with regard to the relative abundances of total peripheral blood mononuclear cells (PBMCs). We observed a significant increase in CD14 + CD16 − myeloid cells during treatment, initially driven by classical monocyte proliferation and subsequently driven by the expansion of monocytic myeloid-derived suppressor cells (M-MDSCs). This M-MDSC expansion occurred only in patients with shorter progression-free survival, who also showed a continuous decrease in central memory T-cell abundances after baseline. Throughout treatment, we observed upregulation of PD-L1 expression on most T-cell subsets in all patients. Higher expression of CD73 and IDO1 on select leukocyte subsets at baseline was significantly positively correlated with longer progression-free survival. Conclusions Our study delineates the phenotypic and functional alterations in peripheral blood leukocytes occurring during combination oleclumab/durvalumab immunotherapy in patients with relapsed EOC. We propose a set of biomarkers with potential for treatment personalization and response monitoring: relative abundances of PBMCs at baseline, relative abundances of M-MDSCs and central memory T cells during treatment; PD-L1 expression levels over time; and baseline expression of CD73 and IDO1 on specific leukocyte subsets. However, validation of these biomarkers through larger-scale studies is required. KEY MESSAGES WHAT IS ALREADY KNOWN ON THIS TOPIC Despite promising preclinical results and moderate efficacy in lung cancer, combination anti-CD73/anti-PD-L1 immunotherapy in relapsed epithelial ovarian cancer (EOC) has shown only modest response rates, consistent with other EOC immunotherapy trials. Durable clinical benefit remains rare, and there are currently no biomarkers available for the effective selection of EOC patients for personalized immunotherapy and for the characterization of sustained responses. WHAT THIS STUDY ADDS This study demonstrates that, at baseline of combination anti-CD73/anti-PD-L1 treatment, EOC patients with higher relative abundances of peripheral blood mononuclear cells (PBMCs) and elevated expression of CD73 and IDO1 on certain PBMC subsets may experience greater overall survival and progression-free survival benefit, respectively. Additionally, patients with faster disease progression exhibited a shift in CD14 + CD16 − myeloid cells towards a more immunosuppressive phenotype and had lower abundances of central memory T cells over time compared to patients with slower progression, while PD-L1 expression increased significantly over time on T cells of all patients, regardless of the

Year:

2024

Year:

2021

Collaborators (10)

Maria Rossing

Associate Clinical Professor

Copenhagen University Hospital

DENMARK
View details

Maarit Anttila

Head of the Gyn

Kuopio University Hospital

FINLAND
View details

Sakari Hietanen

Chief of Dept.

Helsinki University Hospital

FINLAND
View details

Line Bjørge

University of Bergen

NORWAY
View details

Elina Hypponen

Professor

University of South Australia

AUSTRALIA
View details

Mansoor Mirza

Chief Oncologist

Rigshospitalet

DENMARK
View details

Liv Thomsen

Head of Department

Norwegian Institute of Public Health

NORWAY
View details

Emmet McCormack

Chair of Innovation

University of Bergen

NORWAY
View details

Susanne Malander

Skåne University Hospital

SWEDEN
View details

Annika Auranen

-

FINLAND
View details